Radioiodine Therapy of Liver Cancer Cell Following Tissue Specific Sodium Iodide Symporter Gene Transfer and Assessment of Therapeutic Efficacy with Optical Imaging.
- Author:
Byoung Kuk JANG
1
;
You La LEE
;
Yong Jin LEE
;
Sohn Joo AHN
;
Min Jung RYU
;
Sun Mi YOON
;
Sang Woo LEE
;
Jeongsoo YOO
;
Je Yeol CHO
;
Jaetae LEE
;
Byeong Cheol AHN
Author Information
1. Department of Nuclear Medicine, School of Medicine, Kyungpook National University, Daegu, Korea. abc2000@knu.ac.kr
- Publication Type:In Vitro ; Original Article
- Keywords:
tissue specific promoter;
AFP;
radioiodine;
luciferase;
gene therapy;
molecular imaging
- MeSH:
Animals;
Benzothiazoles;
Carcinoma, Hepatocellular;
Gamma Cameras;
Genetic Therapy;
Homicide;
Injections, Intraperitoneal;
Ion Transport;
Light;
Liposomes;
Liver;
Liver Neoplasms;
Luciferases;
Luminescence;
Mice;
Mice, Nude;
Molecular Imaging;
Optical Imaging;
Perchloric Acid;
RNA, Messenger;
Sodium;
Sodium Iodide;
Symporters;
Transfection;
Transplantation, Heterologous;
Transportation
- From:Nuclear Medicine and Molecular Imaging
2008;42(5):383-393
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: Cancer specific killing can be achieved by therapeutic gene activated by cancer specific promotor. Expression of sodium iodide symporter (NIS) gene causes transportation and concentration ofiodide into the cell, therefore radioiodine treatment after NIS gene transfer to cancer cell could be a form of radionuclide gene therapy. luciferase (Luc) gene transfected cancer cell can be monitored by in vivo optical imaging after D-luciferin injection. Aims of the study are to make vector with both therapeutic NIS gene driven by AFP promoter and reporter Luc gene driven by CMV promoter, to perform hepatocellular carcinoma specific radiodiodine gene therapy by the vector, and assessment of the therapy effect by optical imaging using luciferase expression. MATERIALS AND METHODS: A Vector with AFP promoter driven NIS gene and CMV promoter driven Luc gene (AFP-NIS-CMV-Luc) was constructed. Liver cancer cell (HepG2, Huh-7) and non liver cancer cell (HCT-15) were transfected with the vector using liposome. Expression of the NIS gene at mRNA level was elucidated by RT-PCR. Radioiodide uptake, perchlorate blockade, and washout tests were performed and bioluminescence also measured by luminometer in these cells. In vitro clonogenic assay with I-131 was performed. In vivo nuclear imaging was obtained with gamma camera after I-131 intraperitoneal injection. RESULTS: A Vector with AFP-NIS-CMV-Luc was constructed and successfully transfected into HepG2, Huh-7 and HCT-15 cells. HepG2 and Huh-7 cells with AFP-NIS-CMV-Luc gene showed higher iodide uptake than non transfected cells and the higher iodide uptake was totally blocked by addition of perchlorate. HCT-15 cell did not showed any change of iodide uptake by the gene transfection. Transfected cells had higher light output than control cells. In vitro clonogenic assay, transfected HepG2 and Huh-7 cells showed lower colony count than non transfected HepG2 and Huh-7 cells, but transfected HCT-15 cell did not showed any difference than non transfected HCT-15 cell. Number of Huh-7 cells with AFP-NIS-CMV-Luc gene transfection was positively correlated with radioidine accumulation and luciferase activity. In vivo nuclear imaging with I-131 was successful in AFP-NIS-CMV-Luc gene transfected Huh-7 cell xenograft on nude mouse. CONCLUSION: A Vector with AFP promoter driven NIS and CMV promoter driven Luc gene was constructed. Transfection of the vector showed liver cancer cell specific enhancement of I-131 cytotoxicity by AFP promoter, and the effect of the radioiodine therapy can be successfully assessed by non-invasive luminescence measurement.
